Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C4931007 expanded pneumococcal conjugate vaccine safety study in healthy infants
2025-523447-35-02Phase 3Authorised
- Sponsor
- Pfizer
- Start
- Sep 2026
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial in pneumococcal disease comparing PF-07872412 expanded pneumococcal conjugate vaccine with Prevenar 20 active control (2 arms). Primary endpoints: Prespecified local reactions, Prespecified systemic events and 2 more. Planned start Sep 2026; status: authorised.
02
Drugs
PF-07872412Prevnar 20
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2025-523447-35-02.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523447-35-02.